Alpha-lipoic acid and nerve symptoms
What 3 graded rows on alpha-lipoic acid agree on for nerve symptoms, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Alpha-lipoic acid page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Alpha-lipoic acid page, with its PubMed record.
Your question
Alpha-lipoic acid and nerve symptoms
3 rows · 2,239 peopleMostly an improvement: 2 of 3 rows, and most of the people. 1 found no difference.
- AGrade A× 1
- BGrade B× 1
- ∅No effect× 1
- Rows
- 3
- Trials
- 14
- People
- 2,239
- Pooled reviews may count some twice
Where they differ
From the rowsThe best-graded row, grade A, is a meta-analysis of 1,242 people (2023) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.
The row that found no difference is newer (2024) than the 2 rows that found an improvement (2006 to 2023).
The rows
2 improved · 1 no difference- AGrade ADiabetic nerve symptom scores · Improved
Meta-analysis, 10 studies · n 1,242 · 2023 · Adults with diabetic sensorimotor polyneuropathy in 10 RCTs
600–1,800 mg/day · Varied across trials
Total symptom score and global satisfaction improved versus placebo with a dose-related trend; vibration threshold, nerve conduction and NIS-LL did not improve.
Row on the Alpha-lipoic acid page · PubMed 37630823 (opens PubMed)
- BGrade BBurning, stabbing pain and numbness of the feet · Improved
RCT · n 181 · 2006 · Adults with diabetes and distal symmetric polyneuropathy
600, 1,200 or 1,800 mg once daily · 5 weeks
Symptom scores fell more with all three doses than placebo; 600 mg gave the best balance because nausea, vomiting and vertigo rose with dose.
Row on the Alpha-lipoic acid page · PubMed 17065669 (opens PubMed)
- ∅No effectNerve symptoms and impairment after 6 months or longer · No difference
Systematic review, 3 studies · n 816 · 2024 · Adults with type 1 or type 2 diabetes and peripheral neuropathy in 3 placebo-controlled RCTs lasting at least 6 months
Varied across trials (not stated in the abstract) · 6–48 months
Cochrane review: probably little or no effect on symptom scores at 6 months (moderate certainty) and may have little or no effect on impairment (NIS-LL); withdrawals for adverse events did not differ from placebo. All 3 trials were at high risk of attrition bias.
Row on the Alpha-lipoic acid page · PubMed 38205823 (opens PubMed)